Ypsomed (YPSN) H2 25/26 earnings summary

Executive summary

• Achieved record financial results and completed transformation into a focused, pure-play self-injection device company, divesting non-core businesses such as Diabetes Care and Ypsotec.

• Secured a record 44 new project deals, including 12 with new customers across diverse therapeutic areas and geographies.

• Launched three new recyclable device platforms (YpsoLoop, YpsoDot, YpsoFlow), embedding sustainability and innovation in products and operations.

• Expanded global manufacturing footprint with new or expanded facilities in Switzerland, Germany, China, and the US, supporting local-for-local production.

• Created 245 new jobs in Delivery Systems, with workforce optimization following divestments.

Financial highlights

• Reported consolidated sales of CHF 731 million, with Delivery Systems revenue rising to CHF 601 million (20% growth year-over-year).

• Group EBIT reached CHF 246 million, with Delivery Systems contributing CHF 196 million and a 33% EBIT margin.

• Operating cash flow exceeded CHF 300 million, supported by CHF 307 million inflow from Diabetes Care divestment.

• Dividend proposed to double, maintaining a 35% payout ratio (excluding one-time items).

• Net debt/EBITDA reduced to 0.8x, with equity ratio above 55%.

Outlook and guidance

• Delivery Systems sales expected to grow 12–15% in the next year, with EBIT guided between CHF 210 million and CHF 230 million, maintaining EBIT margin above 33%.

• Midterm ambition: CHF 0.9–1.1 billion sales and CHF 280–340 million EBIT by 2029/30, with ROCE around 20%.

• Growth trajectory expected to be linear, with some catch-up in later years.